Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9

Area of Science:

• Genetics
• Molecular Biology
• Biotechnology

Background:

• Myotonic dystrophy type 1 (DM1) is a genetic disorder caused by expanded CTG repeats in the DMPK gene's 3' UTR.
• These repeat expansions lead to toxic RNA species and cellular dysfunction.

Purpose of the Study:

• To investigate therapeutic genome editing strategies for DM1 using CRISPR/Cas9.
• To evaluate targeted deletion of CTG repeats and insertion of polyadenylation signals to mitigate toxic RNA CUG repeats.

Main Methods:

• CRISPR/Cas9 system with SpCas9 or SaCas9 was employed for genome editing.
• Two strategies were tested: targeted deletion of expanded CTG repeats and targeted insertion of polyadenylation signals upstream of the repeats.
• Efficacy was assessed in differentiated neural stem cells, forebrain neurons, cardiomyocytes, and skeletal muscle myofibers.

Main Results:

• Targeted deletion of CTG repeats using CRISPR/Cas9 resulted in frequent inversions in both mutant and normal alleles.
• Insertion of polyadenylation signals effectively eliminated toxic RNA CUG repeats.
• Phenotype reversal was observed in multiple cell types following the polyadenylation signal insertion strategy.

Conclusions:

• Targeted insertion of polyadenylation signals represents a promising therapeutic genome editing approach for DM1.
• This strategy effectively reduces toxic RNA and restores normal cellular function.
• Further development of this method could lead to effective treatments for DM1 patients.